Compass Therapeutics, Inc.

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company's 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial. Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position.

Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program.

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) recommended that Compass conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application (BLA) submission for tovecimig in patients with previously treated, advanced biliary tract cancer (BTC).